Chapter 1 Introduction
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst's Credentials

Chapter 2 Summary and Highlights

Chapter 3 Biology of Cancer
Overview
Risk Factors for Cancer
Pathogenesis of Cancer
Stages of Cancer
The TNM Staging System
Number Staging Systems
Cancer Metastases
Routes of Metastasis
Drug Resistance
Inherent Resistance
Acquired Resistance
Treatment Approaches to Cancer
Non-pharmaceutical Approaches
Surgery for Cancer
Radiotherapy for Cancer
Ablation Therapy
Pharmacological Therapies
Personalized Cancer Therapy (Precision Medicine)

Chapter 4 Market Breakdown by Drug Type
Overview
Chemotherapy
Types of Chemotherapy Pharmaceuticals
Hormone Therapy
Types of Hormone Therapy Pharmaceuticals
Targeted Therapy
Types of Targeted Therapy Pharmaceuticals
Small Molecule Targeted Agents
Monoclonal Antibodies (mAbs)
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors
Targeted Radioligand Therapies
Immunotherapy
Types of Immunotherapy Pharmaceuticals
Immune Checkpoint Inhibitors
Immune-Modulating Small Molecule
Monoclonal Antibodies (mAbs)
Gene Therapies
Global Market for Oncology Pharmaceuticals by Drug Type
Global Market for Targeted Therapy Pharmaceuticals by Drug Type
Global Market for Immunotherapy Pharmaceuticals by Drug Type
Global Market for Chemotherapy Pharmaceuticals
Global Market for Hormone Therapy Pharmaceuticals

Chapter 5 Market Breakdown by Application
Overview
Lung Cancer
Diagnosis
Breast Cancer
Diagnosis
Multiple Myeloma
Diagnosis
Prostate Cancer
Diagnosis
Non-Hodgkin's Lymphoma
Diagnosis
Colorectal Cancer
Diagnosis
Other Cancers
Stomach Cancer
Liver Cancer
Cervical Cancer
Esophageal Cancer
Melanoma
Leukemia
Global Market for Oncology Pharmaceuticals by Cancer Type

Chapter 6 Market Breakdown by Region
Global Markets for Oncology Pharmaceuticals by Region
North America
North American Market for Oncology Pharmaceuticals by Type
Europe
European Market for Oncology Pharmaceuticals by Type
Asia-Pacific
Asia-Pacific Market for Oncology Pharmaceuticals by Type
RoW
RoW Market for Oncology Pharmaceuticals by Type

Chapter 7 Competitive Landscape
Overview
Blockbuster Oncology Pharmaceutical Brands
Blockbuster Oncology Pharmaceuticals Brand Revenue
Blockbuster Oncology Pharmaceutical Brands, by Drug Type
Blockbuster Oncology Pharmaceuticals, by Company
Key Oncology Pharmaceutical Brands
Chemotherapy
Hormone Therapy
Targeted Therapy
Small Molecule Targeted Agents
mAb Targeted Therapy
PARP Inhibitors
Targeted Radioligand Therapies
Immunotherapy
Immune-Modulating Small Molecules
mAb Immune Therapy
Immune Checkpoint Inhibitors
Gene Therapies
Global Market Shares of Leading Companies
Recent Industry Activities

Chapter 8 New Developments and Pipeline Analysis
New Developments
Novel Oncology Drug Approvals
Biosimilar Approvals
Pipeline Analysis
Selected New Drug Molecules in Late Stages of Clinical Development
Most Studied Drug Molecules

Chapter 9 Market Dynamics
Overview
Market Trends and Growth Drivers
Favorable Global Demographics and Aging Population
Greater Incidence of Obesity and Diabetes
Robust Approval of Oncology Pharmaceuticals
Advances in Biochemistry and Genomics
High Unmet Need
Premium Pricing
Collaborations and Licensing Agreements
Mergers and Acquisitions
Challenges
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
High Cost of Biologic Therapies

Chapter 10 Impact of COVID-19 Pandemic
Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Pharmaceuticals Market

Chapter 11 Company Profiles
ABBVIE INC.
AMGEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO.
NOVARTIS AG
PFIZER INC.
SANOFI-AVENTIS
TAKEDA PHARMACEUTICAL CO. LTD.

Chapter 12 Appendix: Acronyms

List of Tables
Summary Table : Global Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 1 : Current Cancer Treatment Options
Table 2 : Types of Hormone Therapy Drugs
Table 3 : Cancer Drug Treatment Classes
Table 4 : Global Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 5 : Global Market for Targeted Therapy Pharmaceuticals, by Type, Through 2026
Table 6 : Global Market for Immunotherapy Pharmaceuticals, by Type, Through 2026
Table 7 : Global Market for Chemotherapy Pharmaceuticals, Through 2026
Table 8 : Global Market for Hormone Therapy Pharmaceuticals, Through 2026
Table 9 : Stages of Lung Cancer
Table 10 : Estimated Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020
Table 11 : Global Market for Oncology Pharmaceuticals, by Cancer Type, Through 2026
Table 12 : North American Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 13 : North American Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 14 : Demographic, Cancer and Healthcare Statistics for Selected European Countries
Table 15 : Estimated Cancer Incidence and Mortality, Age Standardized Rate in EU Countries, by Cancer Type, 2020
Table 16 : European Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 17 : Oncology Statistics, Asia-Pacific, 2020
Table 18 : Notable Cancer Types, Asia-Pacific, 2020
Table 19 : Asia-Pacific Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 20 : Cancer Statistics, South America and Africa, 2020
Table 21 : RoW Market for Oncology Pharmaceuticals, by Type, Through 2026
Table 22 : Blockbuster Oncology Pharmaceuticals, 2020
Table 23 : Number of Blockbuster Oncology Pharmaceutical Brands, by Drug Type, 2020
Table 24 : Selected Blockbuster Oncology Pharmaceuticals, by Company, 2020
Table 25 : Key Chemotherapy Oncology Pharmaceuticals
Table 26 : Key Hormone Therapy Oncology Pharmaceuticals
Table 27 : Key Small Molecule Targeted Oncology Pharmaceuticals
Table 28 : Key mAb Targeted Oncology Pharmaceuticals
Table 29 : Key PARP Inhibitors
Table 30 : Key Targeted Radioligands
Table 31 : Key Immune-Modulating Small Molecule Pharmaceuticals
Table 32 : Key mAb Immune Therapy Oncology Pharmaceuticals
Table 33 : Key Immune Checkpoint Inhibitor Oncology Pharmaceuticals
Table 34 : Key Genetically-Modified Autologous T-Cell Immunotherapy or CAR T-Cell Therapy Oncology Pharmaceuticals
Table 35 : Key Oncolytic Virus Therapy Oncology Pharmaceuticals
Table 36 : Leading Oncology Pharmaceuticals, 2020
Table 37 : Oncology Approvals
Table 38 : Novel Oncology Drug Approvals, Jan. 2019-July 2021
Table 39 : Biosimilar Approvals for Oncology Indications, 2018 and 2020
Table 40 : Selected New Oncology Drugs in Late Stages of Clinical Development
Table 41 : Selected Drug Molecules for Cancer Treatment, by Number of Clinical Trials
Table 42 : New Cancer Cases, U.S., 2018, by Age Group
Table 43 : Recent Deals and Acquisitions, Oncology Pharmaceutical Market, 2019-2021
Table 44 : AbbVie: Oncology Pharmaceuticals Product Portfolio
Table 45 : AbbVie: Oncology Pharmaceuticals Revenue, 2018-2020
Table 46 : Amgen: Oncology Pharmaceuticals Product Portfolio
Table 47 : Amgen: Oncology Pharmaceuticals Revenue, 2018-2020
Table 48 : Astellas: Oncology Pharmaceuticals Product Portfolio
Table 49 : Astellas: Oncology Pharmaceuticals Revenue, 2018-2020
Table 50 : AstraZeneca: Oncology Pharmaceuticals Product Portfolio
Table 51 : AstraZeneca: Oncology Pharmaceuticals Revenue, 2018-2020
Table 52 : Bayer: Oncology Pharmaceuticals Product Portfolio
Table 53 : Bayer: Oncology Pharmaceuticals Revenue, 2018-2020
Table 54 : Bristol-Myers Squibb: Oncology Pharmaceuticals Product Portfolio
Table 55 : Bristol-Myers Squibb: Oncology Pharmaceuticals Revenue, 2018-2020
Table 56 : Eli Lilly and Co.: Oncology Pharmaceuticals Product Portfolio
Table 57 : Eli Lilly and Co.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 58 : Roche: Oncology Pharmaceuticals Product Portfolio
Table 59 : Roche: Oncology Pharmaceuticals Revenue, 2018-2020
Table 60 : Gilead Sciences Inc.: Oncology Pharmaceuticals Product Portfolio
Table 61 : Gilead Sciences Inc.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 62 : Johnson & Johnson: Oncology Pharmaceuticals Product Portfolio
Table 63 : Johnson & Johnson: Oncology Pharmaceuticals Revenue, 2018-2020
Table 64 : Merck & Co.: Oncology Pharmaceuticals Product Portfolio
Table 65 : Merck & Co.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 66 : Novartis: Oncology Pharmaceuticals Product Portfolio
Table 67 : Novartis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 68 : Pfizer: Oncology Pharmaceuticals Product Portfolio
Table 69 : Pfizer: Oncology Pharmaceuticals Revenue, 2018-2020
Table 70 : Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio
Table 71 : Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 72 : Takeda: Oncology Pharmaceuticals Product Portfolio
Table 73 : Takeda: Oncology Pharmaceuticals Revenue, 2019-2021
Table 74 : Acronyms Used in This Report

List of Figures
Summary Figure : Global Market for Oncology Pharmaceuticals, by Type, 2020-2026
Figure 1 : Antibody Drug Conjugate
Figure 2 : Benefits of Immunotherapy
Figure 3 : Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 4 : mAbs Mechanism of Action as Immunotherapy
Figure 5 : Global Market Shares of Oncology Pharmaceuticals, by Type, 2020
Figure 6 : Global Market Shares of Targeted Therapy Pharmaceuticals, by Type, 2020
Figure 7 : Global Market Shares of Immunotherapy Pharmaceuticals, by Type, 2020
Figure 8 : Five-Year Overall Survival Rates, U.S., by Cancer Type
Figure 9 : Global Market Shares of Oncology Pharmaceuticals, by Cancer Type, 2020
Figure 10 : Global Market Shares of Oncology Pharmaceuticals, by Region, 2020
Figure 11 : North American Market Shares of Oncology Pharmaceuticals, by Type, 2020
Figure 12 : European Market Shares of Oncology Pharmaceuticals, by Type, 2020
Figure 13 : Asia-Pacific Market Shares of Oncology Pharmaceuticals, by Type, 2020
Figure 14 : RoW Market Shares of Oncology Pharmaceuticals, by Type, 2020
Figure 15 : Novel Oncology FDA Drug Approvals, 2016-2021
Figure 16 : Clinical Trials, by Cancer Type
Figure 17 : Rate of New Cancer Cases, U.S., 2018, by Age Group
Figure 18 : Novel Oncology Drug FDA Approvals, 2016-2021
Figure 19 : AbbVie's Hematologic Oncology Segment: Annual Revenue, 2018-2020
Figure 20 : Amgen's Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 21 : Astellas' Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 22 : AstraZeneca's Oncology Segment: Annual Revenue, 2018-2020
Figure 23 : Bayer's Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 24 : Bristol-Myers Squibb Oncology Pharmaceutical: Annual Revenue, 2018-2020
Figure 25 : Eli Lilly and Co.'s Oncology Segment: Annual Revenue, 2018-2020
Figure 26 : Roche's Oncology Segment: Annual Revenue, 2018-2020
Figure 27 : Gilead Sciences Inc.'s Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 28 : Johnson & Johnson's Oncology Segment: Annual Revenue, 2018-2020
Figure 29 : Merck & Co.'s Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 30 : Novartis's Oncology Segment: Annual Revenue, 2018-2020
Figure 31 : Pfizer's Oncology Segment: Annual Revenue, 2018-2020
Figure 32 : Sanofi-Aventis' Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 33 : Takeda's Oncology Pharmaceutical: Annual Revenue, 2018-2020